Ally Bridge Group’s Sarepta Therapeutics SRPT Stock Holding History

Ally Bridge Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-72,000	Closed	-$8.99M	–	37
2024 Q3	$8.99M	Sell	72,000 -1,500	-2%	-$207K	4.81%	6
2024 Q2	$11.6M	Buy	+73,500	New	+$9.44M	6.92%	2
2023 Q2	–	Sell	-20,830	Closed	-$2.87M	–	21
2023 Q1	$2.87M	Buy	+20,830	New	+$2.7M	3.76%	10
2022 Q1	–	Sell	-120,000	Closed	-$10.8M	–	28
2021 Q4	$10.8M	Buy	+120,000	New	+$10.3M	3.78%	10

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ally Bridge Group's SRPT Position: Q4 2024 in Review

Ally Bridge Group sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 72,000 shares — an estimated $8.99M sold.

Ally Bridge Group first reported a position in SRPT in Q4 2021 and held it in 4 quarters. The position peaked at $11.6M in Q2 2024. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Ally Bridge Group reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Ally Bridge Group sold 72,000 Sarepta Therapeutics shares in Q4 2024, an estimated $8.99M.
Ally Bridge Group first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 4 quarters.
Ally Bridge Group's Sarepta Therapeutics position peaked at $11.6M in Q2 2024.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Ally Bridge Group's 13F filing for Q4 2024, filed 14 Feb 2025.